Comparative Pharmacology
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus ROBITET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus ROBITET.
OXYTETRACYCLINE HYDROCHLORIDE vs ROBITET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Robitussin (Robitet) is a combination product containing the antitussive dextromethorphan and the expectorant guaifenesin. Dextromethorphan acts centrally on the cough center in the medulla oblongata by increasing the threshold for coughing, primarily through sigma-1 receptor agonism and NMDA receptor antagonism. Guaifenesin increases the hydration of respiratory tract secretions, reducing mucus viscosity and facilitating expectoration.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
Tetracycline hydrochloride: 250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Terminal elimination half-life: 3.5 hours (2.6–4.8 h) in adults; prolonged to 6–12 h in severe renal impairment
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Renal: 30% unchanged; biliary/fecal: 50% as metabolites; remainder metabolized
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic